Paradigm Biocapital Advisors LP Cullinan Oncology, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,321,013 shares of CGEM stock, worth $25.4 Million. This represents 1.4% of its overall portfolio holdings.
Number of Shares
2,321,013
Previous 1,542,805
50.44%
Holding current value
$25.4 Million
Previous $26.9 Million
44.4%
% of portfolio
1.4%
Previous 1.09%
Shares
3 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$83.7 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$63 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$38.9 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$37.4 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$35.9 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $499M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...